Liminatus Pharma and Iris Acquisition Corp "announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed "Liminatus Pharma, Inc.". The combined company's common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a $15M common stock PIPE financing and a $25M convertible note financing to further support Liminatus' business growth strategy. The business combination implies a pro forma enterprise value of the combined company of approximately $334 million. The combined company is expected to receive gross cash proceeds of up to $316M, comprising the $276 million held in Iris' trust account and a concurrent, committed $15 million equity PIPE financing of common stock issued at $10.00 per share and $25M convertible note financing with an initial conversion rate of $11.50 per share of common stock, subject to future adjustments based upon the price of Iris' publicly traded common stock. The combined company will bear deferred underwriting commissions and transaction expenses out of the gross proceeds."

Rackspace Technology "announced that Onica by Rackspace Technology, the cloud services-focused business group, announced today that it has achieved the Amazon Web Service Service Delivery designation for AWS Glue. The AWS Glue Service Delivery designation recognizes that Onica by Rackspace Technology has proven success in helping customers discover consulting partners who have the expertise to deliver AWS Glue for data integration, pipeline, and catalogue use cases. AWS Partners with this designation makes it easy for customers to discover, prepare, and combine data for analytics, machine learning, and application development. AWS Glue provides all the capabilities needed for data integration such that customers can start analyzing their data and putting it to use in minutes instead of months. To receive this designation, Amazon Partner Network members must possess deep AWS experience and deliver solutions seamlessly on AWS."

In an interview on CNBC's Mad Money, Frank Slootman said for a company of Snowflake's scale to be growing at this rate is unprecedented. "The tailwinds we are experiencing in our business are enormous," he noted. "Customers are trying to accelerate and they want us to help them do it." Advertising is "red hot," and there is tremendous demand from that area, he added.

In an interview on CNBC's Mad Money, Marc Benioff said, "We do our best to bring up great talent, but sometimes they have to leave." He noted that the company is seeing "unprecedented" FX headwinds that were never anticipated. Salesforce closed a lot key transactions in the quarter. "We had big wins," he added.

Viracta Therapeutics reported preliminary dose-ranging data from the first two dose levels of the dose escalation part of the Phase 1b/2 study of Nana-val in patients with Epstein-Barr Virus-Positive - or EBV+ - recurrent/metastatic nasopharyngeal carcinoma - R/M NPC. The data are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology Immuno-Oncology Congress in Geneva, Switzerland, from December 7 - 9. The Phase 1b/2 trial's first two dose levels enrolled seven patients with EBV+ R/M NPC, six of whom were evaluable for response at the data cut-off date. Nana-val was well tolerated with no dose limiting toxicities reported. Most common Grade 1-2 AEs were fatigue, nausea, and increased creatinine. Two of six evaluable patients achieved stable disease. Plasma EBV DNA titers decreased or remained stable in both patients achieving SD, while rising in patients with progressive disease. The Phase 1b/2 trial is currently progressing through its third dose escalation cohort, with enrollment in the third dose level completed. Further safety data from the third dose level will be presented in the abstract's corresponding poster at ESMO-IO. The company anticipates initiating the Phase 2 randomized expansion portion of the Phase 1b/2 trial in the second half of 2023.

Oncocyte announced that Ronnie Andrews will step down from his role as CEO and as a director of the company's board of directors effective December 1. In order to ensure a smooth transition effective as of December 2, Joshua Riggs will serve as interim CEO until such time as a new CEO has been identified and retained and Andrews will continue to act a consultant until February 28, 2023. Riggs, who has been Oncocyte's General Manager, Transplant since July 2022 and was the company's Senior Director Business Development from August 2020 until September 2022, is a seasoned business development strategist with significant experience working with early and growth-stage molecular diagnostics companies. From January 2016 to July 2020, he was a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.

In a regulatory filing, Orthofix Medical (OFIX) announced that it received an unsolicited, non-binding indication of interest from two private equity fund sponsors to acquire all of the outstanding equity of Orthofix for $23.00 per share in cash. The non-binding indication of interest was subject to, among other things, the completion of due diligence, to the sole satisfaction of the sponsors, the arranging of debt financing to fund the purchase price, the completion of unspecified regulatory approvals, and internal approvals by the investment committees of the sponsors. As previously announced, Orthofix has entered into a definitive merger agreement with SeaSpine Holdings (SPNE) to combine in an all-stock transaction, pursuant to which, at the close of the transaction, Orthofix stockholders will own approximately 56.5% of the combined business, and SeaSpine stockholders will own approximately 43.5% of the combined business. The transaction is expected to close early in the first quarter of 2023, subject to Orthofix and SeaSpine stockholder approvals and other customary closing conditions. The Orthofix board engaged in a comprehensive and thorough review and evaluation of the indication of interest Orthofix received, in consultation with legal and financial advisers. Following such review and evaluation, the Orthofix board unanimously determined that the SeaSpine merger transaction continues to be in the best interests of Orthofix and its stockholders. The Orthofix board further unanimously determined that it is unable to conclude that the indication of interest is reasonably likely to lead to a superior proposal under the terms of Orthofix's merger agreement with SeaSpine. The Orthofix board reaffirms to stockholders its recommendation in favor of the SeaSpine merger transaction and remains fully committed to completing the transaction with SeaSpine. A special meeting of Orthofix stockholders has been scheduled for January 4, 2023 to vote on a proposal to approve the issuance of Orthofix common stock in the proposed SeaSpine merger transaction.